drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (biological, gene-modified T cells)
drug_description
Autologous, fourth-generation, dual-target chimeric antigen receptor T-cell therapy engineered to recognize CD19 and CD22 on malignant B cells, leading to T-cell activation and cytotoxic killing; administered with optional repeat doses after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, gene-modified T cells engineered with a dual-target chimeric antigen receptor that binds CD19 and CD22 on malignant B cells; CAR engagement triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing. Lymphodepletion supports in vivo expansion and persistence.
drug_name
EB-BH2024 (CD19/CD22 CAR T cells)
nct_id_drug_ref
NCT06213636